It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In pediatric oncology, there is no evidence-based definition of the temperature limit defining fever (TLDF), which itself is essential for the definition of fever in chemotherapy-induced severe neutropenia (FN). Lowering the TLDF can increase the number of FN episodes diagnosed. This prospective, single center observational study collected data on all temperature measurements, complete blood counts (CBCs), and measures of diagnostics and therapy performed at and after FN diagnosis in pediatric oncology patients using a high standard TLDF (39 °C ear temperature). In 45 FN episodes in 20 patients, 3391 temperature measurements and 318 CBCs, plus information on antibiotics, anti-fungal therapy, antipyretics, blood cultures taken and on discharge were collected. These data can mainly be used to study the influence of virtually lowering the TLDF on diagnostic measures, treatment and length of hospitalization in pediatric FN, which in turn are directly related to costs of FN therapy, and quality of life. This approach can be expanded to include as well different definitions of neutropenia.
Measurement(s) | body temperature trait • Blood Cell Count • Diagnostics, Cancer • therapy |
Technology Type(s) | Thermometer Device • complete blood cell count • Observational study |
Factor Type(s) | day and time • outcome |
Sample Characteristic - Organism | Homo sapiens |
Sample Characteristic - Environment | hospital |
Machine-accessible metadata file describing the reported data: 10.6084/m9.figshare.12118473
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Bern University Hospital, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern, Switzerland (GRID:grid.411656.1) (ISNI:0000 0004 0479 0855)
2 Bern University Hospital, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern, Switzerland (GRID:grid.411656.1) (ISNI:0000 0004 0479 0855); Bern University Hospital, Division of Pediatric Nephrology, Department of Pediatrics, Inselspital, Bern, Switzerland (GRID:grid.411656.1) (ISNI:0000 0004 0479 0855)
3 Bern University Hospital, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern, Switzerland (GRID:grid.411656.1) (ISNI:0000 0004 0479 0855); University Children’s Hospital Zurich, Department of Pediatric Oncology, Zurich, Switzerland (GRID:grid.412341.1) (ISNI:0000 0001 0726 4330)
4 Bern University Hospital, Department of Pediatrics, Inselspital, Bern, Switzerland (GRID:grid.411656.1) (ISNI:0000 0004 0479 0855)